美國參議院排定新任食品藥物管理局局長提名聽證會
U.S. Senate Schedules Hearing for New FDA Commissioner
Updated at: September 19, 2026 at 01:00 AM
美國參議院健康、教育、勞工與退休金委員會(HELP委員會)已排定於2026年9月24日舉行確認聽證會,以評估海蒂·歐文頓(Heidi Overton)博士作為食品藥物管理局(FDA)局長提名人的資格。自馬蒂·馬卡里(Marty Makary)博士於2026年5月辭職後,FDA一直缺乏常任領導人,代理局長凱爾·迪亞曼塔斯(Kyle Diamantas)被迫在此動盪時期管理該機構。歐文頓博士是一位預防醫學醫師,目前擔任白宮國內政策委員會副主任,她正面臨嚴格審視。她的提名正值FDA面臨困境之際,過去一年內已有超過3,000名員工離職。議員們特別關注疫苗政策、米非司酮(mifepristone)的監管以及機構政治化的指控等備受矚目的議題。具體而言,委員會主席比爾·卡西迪(Bill Cassidy)對歐文頓博士先前在疫苗建議方面的工作表示保留。由於HELP委員會僅擁有微弱的共和黨多數優勢,預計即將舉行的聽證會將是一場高風險的考驗。新任局長將繼承穩定員工士氣、清理招聘積壓工作以及定義美國公共衛生監管未來的關鍵任務。
The U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) has scheduled a confirmation hearing for September 24, 2026, to evaluate Dr. Heidi Overton as the nominee for Commissioner of the Food and Drug Administration (FDA). The FDA has lacked a permanent leader since the resignation of Dr. Marty Makary in May 2026, leaving acting commissioner Kyle Diamantas to manage the agency during a tumultuous period. Dr. Overton, a preventive medicine physician and current deputy director of the White House Domestic Policy Council, faces significant scrutiny. Her nomination comes at a difficult time for the FDA, which has seen over 3,000 employees depart within the last year. Lawmakers are particularly concerned about high-profile issues such as vaccine policy, the regulation of mifepristone, and allegations of agency politicization. Specifically, committee chair Bill Cassidy has expressed reservations regarding Dr. Overton’s previous work on vaccine recommendations. With the HELP Committee holding only a narrow Republican majority, the upcoming hearing is expected to be a high-stakes test. The new commissioner will inherit the critical tasks of stabilizing staff morale, clearing hiring backlogs, and defining the future of American public health regulation.
